DG Capital Management’s Standard BioTools LAB Stock Holding History

DG Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-233,887	Closed	-$938K	–	26
2020 Q2	$938K	Buy	+233,887	New	+$815K	0.77%	25

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DG Capital Management's LAB Position: Q3 2020 in Review

DG Capital Management sold out of Standard BioTools (LAB) in Q3 2020, closing a stake of 233,887 shares — an estimated $938K sold.

DG Capital Management first reported a position in LAB in Q2 2020 and held it in 1 quarter. The position peaked at $938K in Q2 2020. 134 funds tracked by Wall St. Rank hold LAB as of Q3 2020.

DG Capital Management reported no remaining Standard BioTools position as of Q3 2020 after selling out during the quarter.
DG Capital Management sold 233,887 Standard BioTools shares in Q3 2020, an estimated $938K.
DG Capital Management first reported a position in Standard BioTools in Q2 2020 and held it in 1 quarter.
DG Capital Management's Standard BioTools position peaked at $938K in Q2 2020.
134 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2020.

Based on DG Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.